首发呼吸肌受累伴胸腺瘤重症肌无力1例并文献复习
摘要
<正>重症肌无力(myasthenia gravis,MG)是一种较为常见的自身免疫性疾病,眼肌麻痹、复视是最为常见的首发症状,也可累及面肌、咽喉肌、四肢肌群,以呼吸道症状为首发表现的病例较罕见。除常规药物外,新型免疫抑制剂、生物制剂、血浆置换、机械通气等对于难治性重症肌无力及肌无力危象的救治起到重要的作用。该文报道1例首发呼吸肌
引文
[1]ZOUVELOU V,STAMBOULIS E,SKRIAPA L.MuSK-Ab positive myasthenia:not always grave[J].J Neurol Sci,2013,331(1-2):150-151.
[2]LI Y,ZHANG Y,CAI G,et al.Anti-LRP4 autoantibodies in Chinese patients with myasthenia gravis[J].Muscle Nerve,2017,56(5):938.
[3]OHTA R,MOTOMURA M.Autoantibodies detected in acetylcholine receptor antibodies-negative myasthenia gravis[J].Rinsho Byori,2014,62(3):255-260.
[4]RICHARDS J,HOWARD JF JR.Seronegative myasthenia gravis associated with malignant thymoma[J].Neuromuscl Disord,2017,27(5):417-418.
[5]SZCZUDLIK P,SZYLUK B,LIPOWSKA M,et al.Antititin antibody in early-and onset myasthenia gravis[J].Acta Neurol Scand,2014,130(4):229-233.
[6]YU S,LI F,CHEN B,et al.Eight-year follow-up of patients with myasthenia gravis after thymectomy[J].Acta Neurol Scand,2015,131(2):94-101.
[7]ISMAIL M,SWIERZY M,RUCKERT RI,et al.Robotic thymectomy for myasthenia gravis[J].Thorac Surg Clin,2014,24(2):189-195.
[8]MADENCI AL,LI GZ,WEIL BR.The role of thymectomy in the treatment of juvenile myasthenia gravis:A systematic review[J].Pediatr Surg Int,2017,33(6):683-694.
[9]QI G,LIU P,DONG H,et al.Metastatic Thymoma-Associated Myasthenia Gravis:Favorable Response to Steroid Pulse Therapy Plus Immunosuppressive Agent[J].Medical Science Monitor International Medical Journal of Experimental&Clinical Research,2017,23(8):1217-1223.
[10]CRUZ JL,WOLFF ML,VANDERMAN AJ,et al.The emerging role of tacrolimus in myasthenia gravis[J].Ther Adv Neurol Disord,2015,8(2):92-103.
[11]HOBSON-WEBB LD,HEHIR M,CRUM B,et al.Can mycophenolate mofetil be taperd safely in myasthenia gravis?A retrospective,multicenter analysis[J].Muscle Nerve,2015,52(2):211-215.
[12]NAKAMURA S,KANEKO S,SHINDE A,et al.Prednisolonesparing effect of cyclosporin A therapy for very elderly patients with myasthenia gravis[J].Neuromuscul Disord,2013,23(2):176-179.
[13]SUDULAGUNTA SR,SEPEHRAR M,SODALAGUNTA MB,et al.Refractory myasthenia gravis-Clinical profile,comorbidities and response to rituximab[J].Ger Med Sci,2016,14(12):12.
[14]JONSSON DI,PIRSKANEN R,PIEHL F.Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab[J].Neuromuscul Disord,2017,27(6):565-568.
[15]HAKANSSON I,SANDSTEDT A,LUNDIN F.Successful autologous haematopoietic stem cell transplantation for refractory myasthenia gravis-a case report[J].Neuromuscul Disord,2017,27(1):90-93.
[16]SANDERS DB,WOLFE GI,BENATAR M,et al.International consensus guidance for management of myasthenia gravis:Executive summary[J].Neurology,2016,87(4):419-425.
[17]ROZMILLOWSKA I,ADAMCZYK-SOWA M,RUTKOWSKA K,et al.Improvement of quality of life after therapeutic plasma exchange in patients with myasthenic crisis[J].Neurol Neurochir Pol,2016,50(6):418-424.
[18]YAMADA C,TEENER JW,DAVENPORT RD,et al.Maintenance plasma exchange treatment for muscle specific kinase antibody positive myasthenia gravis patients[J].J Clin Apher,2015,30(5):314-319.
[19]李柱一.中国重症肌无力诊断和治疗指南(2015)[J].中华神经科杂志,2015,48(11):934-940.
[2]LI Y,ZHANG Y,CAI G,et al.Anti-LRP4 autoantibodies in Chinese patients with myasthenia gravis[J].Muscle Nerve,2017,56(5):938.
[3]OHTA R,MOTOMURA M.Autoantibodies detected in acetylcholine receptor antibodies-negative myasthenia gravis[J].Rinsho Byori,2014,62(3):255-260.
[4]RICHARDS J,HOWARD JF JR.Seronegative myasthenia gravis associated with malignant thymoma[J].Neuromuscl Disord,2017,27(5):417-418.
[5]SZCZUDLIK P,SZYLUK B,LIPOWSKA M,et al.Antititin antibody in early-and onset myasthenia gravis[J].Acta Neurol Scand,2014,130(4):229-233.
[6]YU S,LI F,CHEN B,et al.Eight-year follow-up of patients with myasthenia gravis after thymectomy[J].Acta Neurol Scand,2015,131(2):94-101.
[7]ISMAIL M,SWIERZY M,RUCKERT RI,et al.Robotic thymectomy for myasthenia gravis[J].Thorac Surg Clin,2014,24(2):189-195.
[8]MADENCI AL,LI GZ,WEIL BR.The role of thymectomy in the treatment of juvenile myasthenia gravis:A systematic review[J].Pediatr Surg Int,2017,33(6):683-694.
[9]QI G,LIU P,DONG H,et al.Metastatic Thymoma-Associated Myasthenia Gravis:Favorable Response to Steroid Pulse Therapy Plus Immunosuppressive Agent[J].Medical Science Monitor International Medical Journal of Experimental&Clinical Research,2017,23(8):1217-1223.
[10]CRUZ JL,WOLFF ML,VANDERMAN AJ,et al.The emerging role of tacrolimus in myasthenia gravis[J].Ther Adv Neurol Disord,2015,8(2):92-103.
[11]HOBSON-WEBB LD,HEHIR M,CRUM B,et al.Can mycophenolate mofetil be taperd safely in myasthenia gravis?A retrospective,multicenter analysis[J].Muscle Nerve,2015,52(2):211-215.
[12]NAKAMURA S,KANEKO S,SHINDE A,et al.Prednisolonesparing effect of cyclosporin A therapy for very elderly patients with myasthenia gravis[J].Neuromuscul Disord,2013,23(2):176-179.
[13]SUDULAGUNTA SR,SEPEHRAR M,SODALAGUNTA MB,et al.Refractory myasthenia gravis-Clinical profile,comorbidities and response to rituximab[J].Ger Med Sci,2016,14(12):12.
[14]JONSSON DI,PIRSKANEN R,PIEHL F.Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab[J].Neuromuscul Disord,2017,27(6):565-568.
[15]HAKANSSON I,SANDSTEDT A,LUNDIN F.Successful autologous haematopoietic stem cell transplantation for refractory myasthenia gravis-a case report[J].Neuromuscul Disord,2017,27(1):90-93.
[16]SANDERS DB,WOLFE GI,BENATAR M,et al.International consensus guidance for management of myasthenia gravis:Executive summary[J].Neurology,2016,87(4):419-425.
[17]ROZMILLOWSKA I,ADAMCZYK-SOWA M,RUTKOWSKA K,et al.Improvement of quality of life after therapeutic plasma exchange in patients with myasthenic crisis[J].Neurol Neurochir Pol,2016,50(6):418-424.
[18]YAMADA C,TEENER JW,DAVENPORT RD,et al.Maintenance plasma exchange treatment for muscle specific kinase antibody positive myasthenia gravis patients[J].J Clin Apher,2015,30(5):314-319.
[19]李柱一.中国重症肌无力诊断和治疗指南(2015)[J].中华神经科杂志,2015,48(11):934-940.